Table 3.
Relative risks and 95% confidence intervals (CI) of breast cancer subtypes by tertiles of 1990 plasma measure for 1990–2006 follow-up among those with 1990 blood
| # Cases | Tertile of plasma measure1 | P for trend | P for heterogeneity | Per 1-SD increase in natural log-transformed concentrations1 | |||
|---|---|---|---|---|---|---|---|
| 1 (lowest) | 2 | 3 | |||||
| Folate, ng/mL | <6.0 | 6.0 to 11.2 | ≥11.3 | ||||
| Luminal A | 510 | 1.00 (ref.) | 0.87 (0.68–1.12) | 1.05 (0.82–1.34) | 0.47 | 0.41 | 1.01 (0.91–1.12) |
| Luminal B | 182 | 1.00 (ref.) | 0.71 (0.48–1.03) | 0.79 (0.54–1.16) | 0.37 | 0.93 (0.79–1.10) | |
| HER 2 Type | 50 | 1.00 (ref.) | 0.82 (0.40–1.68) | 0.95 (0.47–1.93) | 0.99 | 0.89 (0.66–1.20) | |
| Basal Like | 42 | 1.00 (ref.) | 1.47 (0.68–3.17) | 1.14 (0.49–2.63) | 0.94 | 0.94 (0.68–1.30) | |
| Vitamin B12, pg/mL | <375 | 375 to 530 | ≥531 | ||||
| Luminal A | 508 | 1.00 (ref.) | 1.11 (0.87–1.42) | 1.04 (0.81–1.33) | 0.83 | 0.81 | 1.04 (0.94–1.16) |
| Luminal B | 182 | 1.00 (ref.) | 0.94 (0.64–1.36) | 0.93 (0.64–1.36) | 0.72 | 1.05 (0.90–1.22) | |
| HER 2 Type | 50 | 1.00 (ref.) | 0.83 (0.40–1.75) | 1.20 (0.61–2.38) | 0.52 | 1.12 (0.84–1.49) | |
| Basal Like | 42 | 1.00 (ref.) | 0.80 (0.37–1.70) | 0.72 (0.33–1.54) | 0.40 | 0.86 (0.63–1.17) | |
| Pyridoxal 5′-phosphate, pmol/mL | <31.1 | 31.1 to 57.7 | ≥57.8 | ||||
| Luminal A | 510 | 1.00 (ref.) | 0.86 (0.68–1.10) | 0.88 (0.68–1.12) | 0.40 | 0.45 | 0.98 (0.88–1.08) |
| Luminal B | 182 | 1.00 (ref.) | 0.90 (0.62–1.30) | 0.82 (0.56–1.21) | 0.34 | 0.92 (0.79–1.08) | |
| HER 2 Type | 50 | 1.00 (ref.) | 0.60 (0.30–1.20) | 0.57 (0.28–1.16) | 0.18 | 0.76 (0.55–1.05) | |
| Basal Like | 41 | 1.00 (ref.) | 1.72 (0.77–3.87) | 1.66 (0.73–3.78) | 0.34 | 1.02 (0.74–1.40) | |
| Homocysteine, nmol/mL | <9.5 | 9.5 to 11.8 | ≥11.9 | ||||
| Luminal A | 509 | 1.00 (ref.) | 0.96 (0.75–1.22) | 1.02 (0.80–1.31) | 0.81 | 0.29 | 0.96 (0.86–1.06) |
| Luminal B | 182 | 1.00 (ref.) | 1.08 (0.73–1.60) | 1.22 (0.83–1.79) | 0.31 | 1.11 (0.95–1.30) | |
| HER 2 Type | 50 | 1.00 (ref.) | 0.51 (0.25–1.05) | 0.60 (0.30–1.20) | 0.16 | 0.85 (0.63–1.15) | |
| Basal Like | 42 | 1.00 (ref.) | 0.85 (0.36–2.04) | 1.56 (0.73–3.33) | 0.18 | 1.63 (1.23–2.17) | |
| Cysteine, nmol/mL2 | |||||||
| Luminal A | 510 | 1.00 (ref.) | 1.00 (0.79–1.28) | 0.86 (0.66–1.11) | 0.21 | 0.57 | 0.99 (0.89–1.10) |
| Luminal B | 182 | 1.00 (ref.) | 1.23 (0.85–1.80) | 0.88 (0.58–1.35) | 0.43 | 1.09 (0.93–1.29) | |
| HER 2 Type | 50 | 1.00 (ref.) | 0.84 (0.42–1.68) | 0.66 (0.30–1.41) | 0.28 | 0.86 (0.63–1.18) | |
| Basal Like | 42 | 1.00 (ref.) | 1.57 (0.67–3.69) | 1.84 (0.77–4.38) | 0.20 | 1.24 (0.89–1.72) | |
| Cysteinylglycine, nmol/mL2 | <167.3 | 167.3 to 208.7 | ≥208.8 | ||||
| Luminal A | 505 | 1.00 (ref.) | 0.78 (0.61–1.00) | 0.87 (0.68–1.11) | 0.27 | 0.85 | 0.97 (0.88–1.08) |
| Luminal B | 181 | 1.00 (ref.) | 0.84 (0.57–1.24) | 1.06 (0.73–1.54) | 0.71 | 1.02 (0.87–1.19) | |
| HER 2 Type | 50 | 1.00 (ref.) | 1.22 (0.60–2.47) | 1.13 (0.55–2.34) | 0.76 | 1.04 (0.77–1.41) | |
| Basal Like | 42 | 1.00 (ref.) | 0.91 (0.41–2.04) | 1.13 (0.53–2.42) | 0.73 | 1.17 (0.84–1.62) | |
Adjustments for matching factors, age at menarche (continuous variable), parity/age at first birth (nulliparous, 1–2 children/first birth <25 years, 1–2 children/first birth 25+ years, ≥3 children/first birth <25 years, ≥3 children/first birth 25+ years), age at menopause (<50, ≥50 to <55, or ≥ 55 years), family history of breast cancer in mother or a sister (yes or no), history of benign breast disease (yes or no), height (continuous), body mass index at 18 (<21, 21 to <23, 23+), weight change from age 18 (continuous) and alcohol intake at blood collection (continuous) in 1990.
Tertile cut points: <264.4, 264.4 to 313.0, ≥313.1 Batch 1–3; <228.9, 228.9 to 240.9, ≥241.0 Batch 4.